Table 3:

Selected recent data from anti-BCMA/CD3 bispecific antibodies in clinical trials

	AMG-701	Teclistamab	TNB-383B	REGN5458	CC-93269 [60]	PF-3135 [61]
Schedule	Weekly IV	Weekly IV or SC	IV q3w	Weekly IV	Weekly IV	Weekly SC
Patients	n=85	n=149 (84 IV, 65 SC)	n=58	n=49	n=30	n=30
Median prior lines	6	6	6	5	5	8
ORR at therapeutic dose	36% (3–18 mg; n=55)	73% (1500 μg/kg; n=22)	80% (40–60 mg; n=15)	62.5 % (96 mg; n=8)	89% (10 mg; n=9)	80% (≥215 μg/kg)
Duration of response	NR	NR	NR	6 months	NR	NR
CRS [All (Gr 3+)]	65% (9%)	55% (0%)	45% (0%)	39% (0%)	77% (3%)	73% (0%)
Neurotoxicity [All (Gr 3+)]	6 patients*	5% (1%; in IV cohort)	NR	12% (0%)	NR	20% (0%)

NR: Not reported

^*6 patients reported in abstract in n=75, data not available from oral presentation with n=85